Intravitreal ranibizumab in retinal macroaneurysm |
| |
Authors: | Andrea R. Wenkstern Heike Petersen |
| |
Affiliation: | (1) Eye Center Uzwil, Uzwil, Switzerland;(2) Eye Center Frauenfeld, Frauenfeld, Switzerland;(3) Bahnhofstrasse 83 b, CH-9240 Uzwil, Switzerland |
| |
Abstract: | Purpose To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm. Methods Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema. Functional and morphological data at baseline and at 4 weeks, 3 months, and 5 months after the initiation of therapy with two intravitreal ranibizumab (Lucentis®) injections followed by focal argon laser coagulation surrounding the retinal macroaneurysm are presented. Results Best-corrected visual acuity improved from 20/50 at baseline to 20/20 at 3-month follow-up and maintained stable at 20/25 through 5-month follow-up. Central retinal thickness measured by optical coherence tomography decreased from 510 µm at baseline to 148 µm at 5-month follow-up. Fluorescein angiography demonstrated closure of the retinal macroaneurysm at 6-week follow-up. No ocular or systemic side effects were detected. Conclusions Intravitreal ranibizumab (Lucentis®) therapy may close the retinal macroaneurysm leading to resolution of the associated macular edema and consequently visual improvement. To our knowledge, this is the first case of a retinal macroaneurysm benefiting from treatment with intravitreal ranibizumab (Lucentis®). The observed results warrant further investigation. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|